Unlock instant, AI-driven research and patent intelligence for your innovation.

A compound and its use

A compound, selected technology, applied in the field of compounds

Active Publication Date: 2021-09-21
SCINNOHUB PHARM CO LTD +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] As a new type of IDO inhibitor, BMS-986205 is currently in the phase II clinical research stage, but there is still a lot of room for improvement in its efficacy and pharmacokinetic properties

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A compound and its use
  • A compound and its use
  • A compound and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0245] Example 1: N-(4-chlorophenyl)-2-(3-((6-fluoroquinolin-4-yl)oxy)-8-azabicyclo[3.2.1]oct-8-yl ) The preparation synthetic steps of propionamide are as follows:

[0246]

[0247] Step 1: Preparation of tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate

[0248] At room temperature, TEA (30.4 g, 300.0 mmol) was added dropwise to a mixed solution of nortropinone hydrochloride (16.2 g, 100.0 mmol) and DCM (300 mL), and the temperature of the system was controlled below 30°C. After the addition, add (Boc) in batches to the reaction system 2 O (24.0 g, 110.0 mmol), after the addition was complete, the reaction system was stirred at room temperature for 6 h. TLC shows that after the raw material reaction is completed, the reaction solution is once saturated with 1M dilute hydrochloric acid 2 CO 3 aqueous solution and saturated brine. Anhydrous Na for organic phase 2 SO 4 Drying and concentration under reduced pressure gave 22.1 g (yield: 98%) of the target compou...

Embodiment 2

[0263] Example 2: Endo-R-N-(4-chlorophenyl)-2-((1R, 3R, 5S)-3-((6-fluoroquinolin-4-yl)oxy)-8-aza The preparation of bicyclo[3.2.1]oct-8-yl)propionamide

[0264] The synthesis steps are as follows:

[0265]

[0266] Note: The synthesis method of the three isomers of endo-S (Example 62), exo-R (Example 63), and Exo-S (Example 64) is consistent with Example 2.

[0267] Step 1: Preparation of endo-4-(((1R,3R,5S)-8-azabicyclo[3.2.1]oct-3-yl)oxy)-6-fluoroquinoline

[0268] 3-((6-fluoroquinolin-4-yl)oxy)-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (3.7g, 10.0mmol) in 50mL 4M HCl / EA solution was stirred at room temperature for 6h. TLC showed that after the completion of the reaction, the reaction system was directly concentrated under reduced pressure, and the obtained solid was dissolved in 50 mL of water, and the pH value was adjusted to alkaline with NaOH. The resulting system was extracted with EA (50mL x 5), the organic phase was backwashed once with satu...

Embodiment 3

[0277] Example 3: N-(4-chlorophenyl)-2-(3-((6-fluoroquinolin-4-yl)amino)-8-azabicyclo[3.2.1]oct-8-yl) The preparation synthetic steps of propionamide are as follows:

[0278]

[0279] Step 1: Preparation of tert-butyl 3-((6-fluoroquinolin-4-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate

[0280] Under nitrogen protection, tert-butyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (2.3g, 10.2mmol) and 4-chloro-6-fluoroquinoline (1.8g, 9.9 mmol) in 30 mL DMSO solution was added CuI (0.2 g, 1.0 mol). After the addition was complete, the reaction mixture was stirred at 100° C. for 6 h under nitrogen protection. The reaction system was poured into 200 mL of water and extracted with EA (10 mL x 3). The organic phase was washed with saturated brine, anhydrous Na 2 SO 4 After sufficient drying and concentration under reduced pressure, the residue was purified by column chromatography (PE:EA = 1:1) to obtain 1.1 g (yield: 30%) of the target compound as a yellow solid.

[02...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a new compound, which has certain inhibitory activity on the oxidoreductase indoleamine 2,3-dioxygenase (IDO), or can be used to treat related diseases, including cancer and immune-related disease use.

Description

[0001] The present invention is a later application of the earlier application with the application number CN201711423562.7. The present invention claims the priority of the earlier application, and the content recorded in the earlier application can be used as a supplement to the present invention. technical field [0002] The invention relates to the field of medicinal chemistry, in particular to a compound and its application. Background technique [0003] The full name of IDO is indoleamine 2,3 dioxygenase, which is a monomeric enzyme containing heme and the rate-limiting enzyme of human tryptophan metabolism. Like PD-1, it is also a regulator of tumor immune response Key immunosuppressive enzyme. IDO is silent in most tissues, but IDO is continuously expressed in many tumor cells, resulting in a decrease in intracellular tryptophan levels and the production of a series of metabolites, which in turn affect immune and nervous system functions. [0004] The role of IDO is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/08C07D487/08C07D519/00C07D215/233C07D215/18A61K31/4709A61K31/55A61K31/52A61K31/522A61K31/5377A61K31/517A61K31/47A61P35/00A61P37/00A61P31/12A61P31/18A61P25/24A61P25/22A61P27/12A61P35/02
CPCA61P25/22A61P25/24A61P27/12A61P31/12A61P31/18A61P35/00A61P35/02A61P37/00C07D215/18C07D215/233C07D471/08C07D487/08C07D519/00
Inventor 黄浩喜刘冠锋任俊峰易守兵陈垌珲何权鸿吴鲜财李英富苏忠海
Owner SCINNOHUB PHARM CO LTD